Compare NHTC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | ATNM |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 47.1M |
| IPO Year | 1995 | N/A |
| Metric | NHTC | ATNM |
|---|---|---|
| Price | $3.28 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 69.8K | ★ 224.5K |
| Earning Date | 02-04-2026 | 11-14-2025 |
| Dividend Yield | ★ 24.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,873,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $42,943.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $2.40 | $1.03 |
| 52 Week High | $6.00 | $2.41 |
| Indicator | NHTC | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 57.56 |
| Support Level | $2.94 | $1.37 |
| Resistance Level | $3.32 | $1.69 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 93.44 | 52.78 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and to support active, physical and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and rest from China, Taiwan, Japan, United States and other regions.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.